Russian Journal of ImmunologyRussian Journal of Immunology1028-72212782-7291Russian Society of Immunology612EVALUATION OF INTRAVITREAL RANIBIZUMAB INJECTION INFLUENCE ON TEAR FLUID IMMUNE STATUS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATIONKuznecovA. A.noemail@neicon.ruTurE. V.noemail@neicon.ruIshmakovK. S.noemail@neicon.ruSouth-Ural State Medical UniversityChelyabinsk Regional Clinical Hospital1504201720215916122102020Copyright © 2017, Kuznecov A.A., Tur E.V., Ishmakov K.S.2017Influence of intravitreal injection of vascular endothelial growth factor A inhibitor (VEGF-A) for aged-related macular degeneration treatment on tear fluid immune status, which was evaluated by multiplex analysis with assay of BasicFGF, Eotaxin, G-CSF, GM-CSF, INF-γ, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-1β, IL-1ra, IL- 2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF- a, VEGF was studied. The study showed that given treatment result in a significant decrease in BasicFGF, Eotaxin, IL-13, TNF-α levels in tear fluid in one month.мультиплексный анализслезацитокиныфакторы ростахемокинывозрастная макулярная дегенерацияmultiplex analysistearcytokinesgrowth factorschemokinesage-related macular degeneration[Clemons T. E., Milton R. C., Clein R et al. Risk factors for the incidence of advanced age-related mac-ular degeneration in the Age-Related Eye disease Study (AREDS). AREDS report number 19. Ophthalmology 2005, 112,533-539.][Resnikoff S., Pascolini D., Etya'ale D., et al. Global data on visual impairment in the year 2002. Bulletin of the World Health Organization 2004, 82 (11), 844-851.][Khan M., Agarwal K., Loutfi M., Kamal A. Present and Possible Therapies for Age-Related Macular Degeneration. ISRN Ophthalmology 2014, article ID 608390, 7 pages.][Кузнецов А. А., Тур Е. В., Ишмаков К. С. Оценка уровня цитокинов слезы у условно здоровых лиц в возрасте старше 50 лет. Российский иммунологический журнал 2016, 10, 3(1) (19), 294-296.]